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Abstract
The 92-kDa type IV collagenase (MMP-9) contributes to tumor invasion and metastases and strategies to down-regulate its expression
could ultimately be of clinical utility. Although the expression of this collagenase is regulated by numerous growth factors, the signaling
pathways that transduce these signals are fewer in number and therefore represent pharmacological targets. In this regard, we previously
reported that MMP-9 expression was regulated by the c-jun amino terminal kinase (JNK) signaling cascade. Therefore, we undertook a study
to determine the efficacy of a novel compound (SP600125), which binds to the ATP binding site of all known JNKs, in repressing MMP-9
expression. In OVCAR-3 cells, SP600125 inhibited the PMA-dependent secretion of MMP-9 in a time-dependent manner and over a dose
range that blocked c-Jun phosphorylation and AP-1 binding. SP600125 repressed the activity of a PMA-stimulated MMP-9 promoter-driven
luciferase reporter, suggesting that diminished secretion of this collagenase reflected reduced transcription. Further, the activity of a GAL4-
driven reporter in PMA-treated cells, co-transfected with an expression construct encoding the trans-activation domain of c-Jun fused to the
DNA binding domain of GAL4, was repressed by SP600125. These findings indicate the efficacy of SP600125 in inhibiting c-Jun activation,
DNA-binding and the PMA-dependent induction of MMP-9 expression. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The 92 kDa type IV collagenase (MMP-9) contributes to
tumor cell invasion and metastases [1,2] in part by degrad-
ing extracellular matrix and activating growth factors such
as TGF-h and IL-1B [3]. Expression of MMP-9 is largely
controlled at the transcriptional level [4–9] although post-
transcriptional mechanisms also contribute to overall levels
of this metalloproteinase [10]. The 92-kDa MMP-9 protein
is activated by the removal of a 73-amino acid propeptide at
the amino-terminus by a variety of enzymes including
plasmin and trypsin-2 [11–13]. The active MMP-9 enzyme,
which degrades type III, IV and IV collagens, elastin as well
as proteoglycan [12,14], is subject to regulation of its
activity by physiological inhibitors including TIMPs 1, 2
and 3, which form noncovalent complexes with the enzyme
[15,16].
The expression of MMP-9 is regulated by diverse growth
factors and oncogenes including TNF-a, EGF, v-Src and
Ras [9,17–20] known to signal through the c-jun amino
terminal kinases (JNKs) [21–24]. JNKs in turn, regulate
gene expression by modulating the activity, synthesis and
degradation of a variety of transcription factors including c-
Jun [25,26], JunD [27], ATF2 [28] and PEA3 [29], for
which there are binding sites in the MMP-9 promoter
[17,19].
In cancer, several reports have documented ‘‘hyperac-
tive’’ signaling pathways leading to elevated JNK activity.
For example, JNK activity is increased 23-fold in colonic
neoplasms [30,31]. Moreover, in a recent study it was
demonstrated that blockade of the receptor for advanced
glycation end products (RAGE), which suppressed JNK
activity, decreased tumor metastases [32]. Thus, pharmaco-
logical strategies to block JNK activity could ultimately be
of therapeutic value by diminishing MMP-9 synthesis and
tumor invasiveness. We therefore undertook a study to
determine the efficacy of a recently described [33] small
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molecular weight inhibitor (SP600125) of JNK activity in
suppressing MMP-9 synthesis.
2. Materials and methods
2.1. Plasmids and reagents
The PathDetectk (Stratagene, La Jolla, CA) system used
was the c-Jun-trans-Reporting System (#219000) and con-
sists of the following components: (a) a luciferase reporter
plasmid containing five tandem repeats of the yeast GAL4
binding site upstream of the luciferase gene, (b) an expres-
sion construct encoding either the DNA-binding domain of
GAL4 only or the activation domain of c-Jun fused to the
GAL4 DNA-binding domain. The MMP-9-luciferase
reporter was as described elsewhere [17] with the exception
that the promoter fragment was subcloned into pGL3. The
SP600125 (anthra [1,9-cd] pyrazol-6(2H)-one) and the N1-
methyl substituted pyrazolanthrone (used as a control) were
kindly provided by Celgene Corporation (San Diego, CA).
2.2. Tissue culture
The OVCAR-3 cell line was derived from a malignant
ascites of a patient with progressive adenocarcinoma of the
ovary. All cells were maintained in McCoy’s medium 5A
supplemented with 10% FBS. For the collection of condi-
tioned medium, cells were changed to serum-free medium
[34] and 48 h later, the conditioned medium was collected
and the cells counted.
2.3. Transient reporter assays
OVCAR-3 cells were transfected by a calcium phosphate
method [19] with a luciferase reporter construct fused to the
670-base pair (wild-type) human MMP-9 promoter. Addi-
tion of SP600125 and PMA were performed 15 h post-
transfection. Subsequently, cells were harvested, lysed 24 h
later and luciferase activity assayed using the Dual-lucifer-
ase Reporter Assay System (Promega, Madison, WI) as
instructed. For each transfection, 1 ng of Renilla luciferase
reporter pRL-TK was included to normalize for differences
in tranfection efficiency.
2.4. Zymography
These assays were performed as described by us pre-
viously [5]. Briefly, conditioned medium was electrophor-
esed in a polyacrylamide gel containing 1 mg/ml gelatin.
The gel was then washed at room temperature for 2 h with
2.5% Triton X-100 and subsequently at 37 jC overnight in a
buffer containing 10 mM CaCl2, 150 mM NaCl, and 50 mM
Tris–HCl, pH 7.5. The gel was stained with 0.2% Coomas-
sie blue and photographed on a light box. Proteolysis was
detected as a white zone in a dark blue field.
2.5. EMSA
Nuclear extract was prepared essentially as described
elsewhere [5]. Cultured cells were collected by centrifuga-
tion, washed and suspended in a buffer containing 10 mM
Hepes (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA, 1 mM DTT and 0.5 mM PMSF. After 15 min on ice,
the cells were vortexed in the presence of 0.5% Nonidet NP-
40. The nuclear pellet was then collected by centrifugation
and extracted in a buffer containing 20 mM Hepes pH 7.9,
0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT and 1
mM PMSF for 15 min at 4 jC.
Nuclear extract (10–20 Ag) was preincubated at 4 jC for
30 min with a 100-fold excess of an unlabeled oligonucleo-
tide spanning the  79 MMP-9 cis element of interest. The
sequences were as follows: AP-1, CTGACCCCTGAGT-
CAGCACTT; NF-nB, CAGTGGAATTCCCCAGCC. After
this time, the reaction mixture was incubated at 4 jC for 20
min in a buffer (25 mM Hepes buffer pH 7.9, 0.5 mM
EDTA, 0.5 mM DTT, 0.05 M NaCl and 2.5% glycerol) with
2 Ag of poly dI/dC and 5 fmol (2 104 cpm) of a Klenow
end-labeled (32P-ATP) 30-mer oligonucleotide, which spans
the DNA binding site in the MMP-9 promoter. The reaction
mixture was electrophoresed at 4 jC in a 6% polyacryla-
mide gel using a TBE (89 mM Tris, 89 mM boric acid and 1
mM EDTA) running buffer. The gel was rinsed with water,
dried and exposed to X-ray film overnight.
2.6. Western blotting
Western blotting was performed as described previously
by us [5] using nuclear extracts prepared as described by
this laboratory recently [5]. The antibodies used to detect
phosporylated c-Jun and total c-Jun amounts were #9260
and #9162 from Cell Signaling Technology (Beverly, MA),
respectively.
3. Results
3.1. SP600125 blocks the PMA-dependent induction of
MMP-9 enzyme activity
We previously reported that in the OVCAR-3 cell line,
induction of MMP-9 expression is JNK-dependent but ERK-
independent [19]. Further, PMA strongly activates JNK in
these cells [35]. Therefore, to determine the efficacy of
SP600125 in blocking the regulation of MMP-9 expression
by JNK-dependent signaling pathways, OVCAR-3 cells
were treated with PMA in the absence, or presence, of
varying concentrations of SP600125. This agent is effective
against JNKs 1, 2 and 3 [33]. Conditioned medium was
harvested and analyzed for MMP-9 levels by zymography.
MMP-9 activity was undetectable in the conditioned medium
from untreated cells (Fig. 1A) whereas PMA treatment
caused a robust increase in activity of a metalloproteinase
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indistinguishable in size fromMMP-9 (Fig. 1A). Inclusion of
the JNK inhibitor (SP600125) effectively countered the
PMA-dependent induction of MMP-9 activity in a dose-
dependent manner. Thus, SP600125 at 10 AM nearly abol-
ished the induction by phorbol ester while 20 AM completed
ablated the inductive effect of PMA. Interestingly, we also
noted a repressive effect on MMP-2 expression (Fig. 1A)
although the effect was less pronounced than on MMP-9. As
a control, we tested the effect of the chemically related N1-
methyl substituted pyrazolanthrone (which does not inhibit
JNKs) [33] on PMA-inducible MMP-9 expression. This
control compound had no effect on MMP-9 induction by
PMA (Fig. 1A). The effect of SP600125 was time-dependent
with a reduction of stimulation evident after 2 days of
treatment with the JNK inhibitor (Fig. 1B). This longer time
required to see an effect of SP600125 by zymography may be
related to pre-stored MMP-9 protein coupled to a long half-
life (19–33 h) for this mRNA [10].
Parallel experiments showed that the concentration of
SP600125 that blocked the PMA-induction of MMP-9
expression also suppressed c-Jun phosphorylation (Fig.
1C) reminiscent of that evident with IL-1-stimulated fibro-
blast-like synoviocytes [36]. Thus, it is likely that SP600125
counters the PMA-dependent induction of MMP-9 expres-
sion by way of inhibiting JNK activity. Indeed, the concen-
trations found to be effective in this study are in the same
range as that used to inhibit JNK in experimental models of
rheumatoid arthritis [36].
3.2. SP600125 inhibits activation of the MMP-9 promoter
by phorbol ester
To determine whether the inhibition of MMP-9 enzyme
activity achieved with SP600125 was due to decreased
transcription, OVCAR-3 cells were transiently transfected
with a MMP-9 promoter-driven luciferase reporter and
subsequently treated with PMA in the absence, or presence,
of SP600125. The phorbol ester strongly increased reporter
activity, which was attributed to the MMP-9 promoter
sequence since it was not evident with the pGL3 reporter
only (Fig. 2). However, treatment of the OVCAR-3 cells
with SP600125 reduced the stimulation by over 67%. These
Fig. 1. SP600125 reduces PMA-dependent MMP-9 secretion and inhibits c-Jun phosphorylation. Panel A: OVCAR-3 cells in 10% FBS were treated for 2 days
with the indicated concentration of SP600125 or the chemically-related N1-methyl substituted pyrazolanthrone as a control. Cells were subsequently changed
to serum-free medium supplemented with SP600125 in the absence, or presence, of PMA. After an additional 24 h, conditioned medium was harvested and
cells counted. Aliquots of conditioned medium normalized for any differences in cell number were subjected to zymography. SP600125 treatment caused
< 30% reduction in cell number over this period. Panel B: The experiment was carried out as for Panel A with the exception that the time with SP600125 was
varied. Panel C: OVCAR-3 cells treated with PMA in the absence, or presence, of SP600125 for the indicated times, were harvested and nuclear extract (30 Ag)
analyzed for either phospho-c-Jun or total c-Jun amounts by Western blotting. The data are typical of triplicate experiments.
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data suggest that the repressive effect of the SP600125 is
due, at least in part, to reduced transcription of the MMP-9
gene. Similar findings have been reported for IL-1-induced
expression of a separate collagenase (MMP-1) in fibroblast-
like synoviocytes [36].
3.3. SP600125 decreases transcription factor binding to the
MMP-9 AP-1 motif
We previously reported that JNK regulated MMP-9
expression, in part, through an AP-1 motif at  79 in the
collagenase promoter [37]. Therefore, it is likely that the
repressive effect of SP600125 on MMP-9 expression was
mediated, at least in part, through this motif. To address this
question, we first performed mobility shifting assays. An
oligonucleotide derived from the MMP-9 promoter sequence
spanning this motif was bound specifically with nuclear
factors derived from PMA-stimulated OVCAR-3 cells (Fig.
3A). This binding was specific since it was abolished with an
excess of a nonradioactive oligonucleotide spanning a con-
sensus AP-1 motif but not with an NF-nB-bearing oligonu-
cleotide sequence. Nuclear extract from OVCAR-3 cells
treated with PMA showed increased binding to the AP-1
motif in a time-dependent manner (Fig. 3B). Further,
SP600125 effectively countered the increased AP-1 binding
(Fig. 3B). These data would suggest that SP600125 blocks
MMP-9 expression at least in part by decreasing DNA bind-
ing and/or increased degradation of members of the AP-1
family [26].
Fig. 2. Repression of PMA-stimulated MMP-9 promoter activity by
SP600125. OVCAR-3 cells were transiently co-transfected with 1 ng of a
Renilla luciferase reporter and 1 Ag of MMP-9 promoter-driven luciferase
reporter (MMP-9 pGL3) or the plasmid lacking the promoter sequence
(pGL3). After 15 h, the cells were treated with, or without, 20 AMSP600125
for 1 day. Subsequently, all dishes were treated with 100 nM PMAwith, or
without, the SP600125 for an additional 24 h, the cells harvested and assayed
for luciferase activity after normalization for difference in transfection
efficiency. The data are representative of duplicate experiments.
Fig. 3. Transcription factor binding to the MMP-9 AP-1 motif. Panel A: Nuclear extract (20 Ag) prepared form OVCAR-3 cells treated for 1 day with 100 nM
PMA was mixed with a radioactive oligonucleotide spanning the MMP-9 AP-1 motif (located at  79). Varying amounts of unlabeled oligonucleotide
competitors corresponding to AP-1 or NF-nB consensus motifs were added simultaneously. Bound complexes were subsequently analyzed by electrophoresis.
Panel B: OVCAR-3 cells were pre-treated for 1 h with SP600125 and then supplemented with PMA (final concentration-100 nM PMA) for the indicated times.
Nuclear extract from the cells were generated and analyzed by EMSA as described for Panel A.
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3.4. SP600125 inhibits the MMP-9 promoter by decreasing
the activity of the c-Jun
JNK can also increase AP-1-dependent gene expression
by stimulating transcriptional activity of c-Jun subsequent
to its phosphorylation at the N-terminus trans-activation
domain [24,25]. Therefore, we considered the possibility
that the antagonistic effect of SP600125 on PMA-dependent
induction of MMP-9 expression was also via such a
mechanism. To address this possibility, OVCAR-3 cells
were transiently transfected with an expression construct
encoding a chimeric protein consisting of the trans-activa-
tion domain of c-Jun fused to the GAL4 DNA binding
domain and a luciferase reporter driven by GAL4 binding
sites. Cells were subsequently treated with PMA with, or
without, SP600125. It is apparent from Fig. 4 that stim-
ulation of the GAL4-driven reporter by the c-Jun-GAL4
chimeric protein was diminished (over 67%) by the JNK
inhibitor. These data are consistent with the notion that
SP600125 represses PMA-dependent MMP-9 expression by
reducing both AP-1 binding as well as the trans-acting
activity of c-Jun.
4. Discussion
Although the expression of proteases such as MMP-9 is
regulated by diverse growth factors and protooncogenes,
studies have shown that the signal transduction pathways
employed to transduce these signals are much more limited
in number. Thus, the design of small molecular weight
inhibitors that target the common signal transduction path-
ways could be of clinical utility in invasive cancers by
blocking the concurrent input of diverse stimuli. The study
herein clearly demonstrates the ability of SP600125, the first
reported JNK inhibitor, to reduce MMP-9 expression in an
ovarian cancer cell line.
While our findings indicate that the ability of SP600125
to reduce MMP-9 expression is achieved via reduced AP-1
binding as well as diminished trans-activation of the MMP-
9 promoter by c-Jun, it is very possible that other transcrip-
tional mechanisms are at play. Indeed, the JNK pathway
targets multiple transcription factors including JunD [27],
ATF2 [28] and PEA3 [29], and putative binding sites for
these DNA-binding proteins are present in the MMP-9
promoter. Further, we cannot rule out posttranslational
mechanisms in the MMP-9 regulation since the SP600125
completely abolished the PMA-dependent stimulation of
collagenase activity, as evident in zymography, while reduc-
ing promoter activity to a lesser extent.
Considering the overwhelming evidence for a role of this
type IV collagenase in tumor cell invasion, SP600125 or
congeners may prove highly effective in reducing the in
vivo invasiveness of cancers. However, it is also plausible
that other signaling pathways may act in redundant path-
ways to drive MMP-9 expression, thereby compromising
the efficacy of SP600125 or related agents. Indeed, our
previous studies as well as others [38,39] have shown that
p38 and ERK-dependent signaling pathways also contribute
to MMP-9 expression albeit in cell types from other organ
systems. Further, while we demonstrated the efficacy of
PD098059 in inhibiting the in vivo invasiveness of squ-
amous cell carcinoma of the oral cancer [40], we were
unable to completely block the progression of the disease
with this MEK1 inhibitor. Thus, it may be that strategies that
concurrently target multiple signaling pathways will be
required to overcome any functional redundancy between
signaling cascades.
Notwithstanding these considerations, our findings indi-
cate the efficacy of a small molecular weight compound,
which selectively targets JNK without affecting the ERKs
[33], in repressing PMA-dependent MMP-9 expression.
Considering the strong evidence for a role for JNK in
promoting the progression of some cancers including
colonic malignancies [30,31], it will be interesting to
determine the pre-clinical efficacy of SP600125 or conge-
ners in diminishing the invasive phenotype.
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Fig. 4. SP600125 reduces the transcriptional activity of c-Jun. OVCAR-3
cells were transiently co-transfected with a GAL4-regulated luciferase
reporter (1 Ag) and 5 Ag of an expression vector encoding either the DNA
binding domain of GAL4 (pFCdbd) or the trans activation domain of c-Jun
fused to the GAL4 DNA binding domain (pFAc-Jun). After 16 h, the cells
were treated where indicated with SP600125 (20 AM). After an additional
24 h, the cells were treated with SP600125 with, or without, 100 nM PMA.
Cells were lysed 1 day later and protein (10 Ag) analyzed for luciferase
activity. The data are representative of duplicate experiments.
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